A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511). Issue 1 (July 2015)

• Record Type: Journal Article
• Authors: Owonikoko, Taofeek K.; Dahlberg, Suzanne E.; Khan, Saad A.; Gerber, David E.; Dowell, Jonathan; Moss, Rebecca A.; Belani, Chandra P.; Hann, Christine L.; Aggarwal, Charu; Ramalingam, Suresh S.
• Is Part Of: Lung cancer. Volume 89:Issue 1(2015:Jul.)
• Page Start: 66
• Page End: 70
• Publication Date: 2015-07
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.04.015
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">PARP inhibitor potentiated DNA damaging agents in preclinical models of SCLC.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">The combination of veliparib, cisplatin, and etoposide was safe in untreated SCLC.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The recommended phase II dose (RP2D) of this combination regimen is now established.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Veliparib (100 mg bid), cisplatin (75 mg/m²), and etoposide (100 mg/m²) is the RP2D.</p> </list-item> </list> </p> </sec> </abstract>